AMC MCQ (CAT) psychiatry questions

This man has depressed mood or anhedonia (loss of interest in fishing) plus at least five additional symptoms (sleep disturbance, appetite/weight change, fatigue, worthlessness, poor concentration) present nearly every day for more than two weeks, meeting DSM-5 criteria for a major depressive episode. Somatic presentations such as fatigue, pain and appetite change are common presenting complaints for depression in primary care, especially in men who may not spontaneously report low mood. Normal thyroid function and full blood count exclude an organic mimic. Recognising depression masked by somatic symptoms is essential to avoid unnecessary investigation and delayed treatment.

• A. Chronic fatigue syndrome requires fatigue as the central unexplained feature without the pervasive mood and cognitive symptoms seen here.
• C. Somatic symptom disorder requires excessive health anxiety about symptoms, which is not described in this vignette.
• D. Anxiety is not the dominant feature here; there is no prominent worry or autonomic hyperarousal described.
• E. Thyroid function tests are normal, excluding this metabolic cause of similar symptoms.

Therapeutic Guidelines recommend an SSRI as first-line pharmacotherapy for uncomplicated major depressive disorder because of their favourable efficacy and tolerability profile compared with older agents. Sertraline is commonly favoured due to a relatively low interaction potential and a safer profile in overdose. Tricyclic antidepressants such as amitriptyline are more cardiotoxic in overdose and have greater anticholinergic burden, reserving them for cases where SSRIs fail. Monoamine oxidase inhibitors carry significant dietary and drug interaction risks and are not first-line.

• A. Diazepam is a benzodiazepine that treats anxiety symptoms but has no proven antidepressant effect and carries dependence risk.
• C. Quetiapine is an atypical antipsychotic sometimes used as adjunct in resistant depression, not as monotherapy first-line treatment.
• D. Moclobemide is a reversible MAOI reserved for cases unresponsive to first-line agents because of interaction risks.
• E. Amitriptyline is a tricyclic antidepressant with more anticholinergic side effects and greater danger in overdose, so it is not first-line.

Serotonin syndrome results from excess serotonergic activity in the central nervous system, classically triggered by combining an SSRI with another serotonergic agent such as tramadol, which inhibits serotonin reuptake in addition to its opioid activity. The triad of autonomic instability (fever, tachycardia, diaphoresis), neuromuscular abnormalities (clonus, hyperreflexia, tremor) and altered mental state (agitation) distinguishes it clinically. Onset is typically rapid, within hours to a few days of starting or increasing the interacting drug, as seen here. Management involves stopping both serotonergic agents, supportive care and benzodiazepines, with cyproheptadine for severe cases.

• A. Anticholinergic toxicity causes dry skin and mydriasis but not the clonus and hyperreflexia seen here, and diaphoresis is characteristically absent.
• B. Neuroleptic malignant syndrome is linked to antipsychotic use and classically presents with lead-pipe rigidity and hyporeflexia rather than clonus and hyperreflexia.
• D. Malignant hyperthermia occurs with volatile anaesthetics or suxamethonium exposure, not with oral antidepressant and analgesic combinations.
• E. Opioid withdrawal causes autonomic arousal but not fever to this degree, clonus or hyperreflexia, and the patient has just started an opioid, not stopped one.

Abrupt cessation of an SSRI, particularly one with a short half-life such as paroxetine, commonly produces a discontinuation syndrome within days of stopping or missing doses. Characteristic features include dizziness, nausea, irritability and the distinctive 'brain zaps' or electric shock sensations, often with eye movement. These symptoms typically resolve with reintroduction of the antidepressant followed by a gradual taper, rather than abrupt withdrawal in future. This presentation is distinct from a relapse of the underlying anxiety disorder, which would not typically include the sensory 'zap' phenomenon or occur so acutely after a missed dose.

• A. Serotonin syndrome occurs with excess serotonergic activity, not cessation, and would feature fever, clonus and hyperreflexia, which are absent here.
• B. Vestibular neuritis causes true vertigo with nystagmus and nausea but does not explain the electric shock sensations or temporal link to stopping medication.
• C. There is no description of loss of consciousness, convulsive movements or postictal state to suggest a seizure.
• E. Recurrence of anxiety would not typically produce the sudden sensory 'electric shock' phenomenon and would not have such an abrupt onset tied to a missed dose.

The Edinburgh Postnatal Depression Scale (EPDS) is the recommended validated screening tool for postnatal depression in Australian primary care, administered routinely at around 6-8 weeks postpartum regardless of whether the woman volunteers symptoms, since under-reporting is common. A total score of 13 or more out of a possible 30 indicates a high likelihood of depression and warrants further clinical assessment, while scores of 10-12 warrant monitoring and review. The scale also includes a specific question on self-harm thoughts that should always be reviewed regardless of total score. Universal, structured screening at this timepoint improves detection compared with relying on spontaneous disclosure.

• A. A cutoff of 6 is too low and would generate excessive false positives; the validated threshold for likely depression is 13 or above.
• B. The Hamilton scale is a clinician-administered research and specialist tool, not the recommended primary care screening instrument.
• C. The EPDS, not the PHQ-9, is the specifically validated and recommended tool for postnatal screening, and it should be offered universally rather than only on request.
• E. The GHQ-28 is a general measure of psychological distress, not the specific validated tool recommended for postnatal depression screening in general practice.

Sertraline is generally preferred as first-line pharmacotherapy for depression in breastfeeding women because it is transferred into breast milk in very low concentrations and has the largest body of reassuring safety data in lactation with minimal infant plasma levels detected. Fluoxetine has a long half-life and active metabolite that accumulate in the infant, making it less preferred despite being effective and safe outside lactation. Doxepin is specifically avoided during breastfeeding due to case reports of infant sedation and respiratory depression. Citalopram and venlafaxine are excreted into milk in relatively higher amounts and are not preferred first choices when a safer alternative exists.

• A. Doxepin is specifically contraindicated in breastfeeding due to reports of infant sedation and respiratory depression.
• C. Citalopram is excreted into breast milk in higher relative amounts than sertraline and is not the preferred first-line choice.
• D. Venlafaxine and its active metabolite are excreted into breast milk in higher concentrations, making it a less favoured option when safer alternatives exist.
• E. Fluoxetine's long half-life and active metabolite lead to higher accumulation in breastfed infants, making it a less preferred first choice.

This presentation meets criteria for a manic episode: elevated or irritable mood with increased activity lasting at least 7 days, or any duration if hospitalisation is required, accompanied by symptoms such as decreased need for sleep, pressured speech, grandiosity and excessive involvement in risky activities with harmful consequences. The key distinguishing feature from hypomania is severity, specifically marked impairment in social or occupational functioning, as shown by his inability to work and the altercation with a colleague, which is sufficient to diagnose bipolar I disorder. Hypomania, by definition, does not cause this degree of functional impairment and does not require hospitalisation. There is no history given of substance use or an identifiable acute stressor to suggest the other diagnoses.

• A. Hypomania by definition does not cause marked impairment in functioning, whereas this man has lost his ability to work and had a workplace altercation.
• B. There is no history of substance use provided to support a substance-induced mood disorder.
• C. Cyclothymic disorder involves chronic, fluctuating subthreshold mood symptoms over at least two years, not an acute severe episode like this.
• E. Acute stress reaction follows a specific traumatic stressor and does not produce this constellation of elevated mood, grandiosity and decreased sleep need.

This patient has active suicidal ideation with a specific, lethal, accessible method and a completed suicide note, which constitutes imminent high risk requiring immediate action. The appropriate response is urgent same-day psychiatric assessment, typically via emergency department or crisis team, combined with immediate steps to remove access to the firearm and ensure continuous supervision until he is assessed. Delaying intervention, relying on self-initiated helpline contact, or starting medication without addressing the immediate safety risk fails to manage the acuity of this presentation. Means restriction, such as removing or securing the firearm, is a key evidence-based intervention to reduce imminent suicide risk.

• A. Starting an SSRI does not address the acute safety risk and has delayed onset of benefit.
• B. A 48-hour delay is unsafe given the immediacy and lethality of his plan.
• C. A fortnight delay for psychology referral does not address the immediate risk to life.
• D. Relying on the patient to self-refer to a helpline is insufficient given his stated lack of reasons to live.

This patient meets criteria for involuntary assessment and treatment under state and territory mental health legislation, as she has a mental illness causing impaired decision-making capacity, poses an imminent and serious risk of harm to herself, and there is no less restrictive means of ensuring her safety given her refusal of voluntary care. Australian mental health acts across jurisdictions allow for emergency detention and assessment when a person's mental illness is driving behaviour that places them at immediate risk of serious harm and they lack capacity to make safe decisions about their care. Discharge or informal family supervision would not provide adequate safety given the severity and immediacy of risk, and a scheduled future order does not address the current emergency.

• A. A delayed community order does not address the immediate need for a safe, supervised environment.
• B. Her right to refuse treatment is overridden when impaired capacity from mental illness leads to imminent serious risk of harm.
• C. Family supervision is not a substitute for clinical risk management in an acute, high-risk psychiatric emergency.
• E. A safety plan is inadequate given her stated ongoing intent and impaired capacity.

In Australian practice, a mature minor who demonstrates sufficient understanding can consent to confidential healthcare, but confidentiality is not absolute and must be balanced against safety, particularly with ongoing self-harm. The appropriate approach is to engage her in a supportive discussion about involving a parent or trusted adult, explore the self-harm in detail, and develop a safety plan, while being clear that confidentiality would need to be breached if risk escalates to a level that threatens her safety, such as emerging suicidal intent or more severe injury. Breaching confidentiality immediately without clinical justification undermines the therapeutic relationship and is not required when there is no current safety-overriding risk, whereas treating confidentiality as entirely fixed ignores the clinician's ongoing duty of care. This approach aligns with RACGP guidance on adolescent health and confidentiality.

• B. Confidentiality for mature minors is not absolute and must be reassessed as risk changes.
• C. Contacting third parties without consent breaches confidentiality inappropriately when there is no immediate safety-overriding risk.
• D. Refusing care unless a parent is involved may discourage the adolescent from seeking help at all.
• E. Automatic disclosure regardless of risk level is not required and may damage trust and future help-seeking.

Aboriginal and Torres Strait Islander youth experience markedly higher rates of suicide than non-Indigenous Australians, and risk is compounded by recent community loss through suicide, disconnection from country, family and culture, and barriers to accessing culturally safe care. Best practice involves thorough risk assessment combined with engagement of local Aboriginal health workers, Aboriginal Community Controlled Health Organisations, and social and emotional wellbeing programs that address cultural and community-specific factors alongside clinical care. Referral to a mainstream service alone, without cultural engagement, may not address his sense of disconnection or engage him effectively, and reassurance without proper assessment underestimates his risk given recent community exposure to suicide, known as a potential cluster risk factor. A collaborative approach respecting cultural context improves engagement and outcomes.

• A. A purely mainstream referral without cultural engagement may not adequately address his connection to culture and community-specific risk factors.
• C. Discharging without follow-up is inappropriate given active risk factors and recent community loss.
• D. Returning home without assessment or support does not address his immediate psychological distress and risk.
• E. Passive suicidal ideation following a community suicide death warrants thorough assessment, not simple reassurance.

Generalised anxiety disorder is characterised by excessive, difficult-to-control worry about multiple areas of life occurring on most days for at least six months, accompanied by physical symptoms such as muscle tension, restlessness, irritability and poor concentration. This pattern of persistent, free-floating worry without discrete panic attacks distinguishes it from panic disorder, which involves recurrent sudden episodes of intense fear with acute somatic symptoms and often anticipatory anxiety about future attacks. The absence of discrete attacks, situational avoidance or social-specific fears rules out the other anxiety diagnoses, and normal thyroid function excludes a medical mimic of anxiety symptoms.

• A. Social anxiety disorder is specific to fear of social or performance situations, which is not described here.
• B. Panic disorder requires recurrent discrete panic attacks with acute intense fear, which this patient does not describe.
• D. Specific phobia involves fear related to a particular object or situation, not generalised worry across multiple domains.
• E. Agoraphobia involves fear and avoidance of situations where escape might be difficult, which is not present in this history.

Panic disorder is best managed long-term with cognitive behavioural therapy (CBT), which addresses catastrophic misinterpretation of bodily sensations and avoidance behaviour, with an SSRI added as first-line pharmacotherapy if psychological therapy alone is insufficient or symptoms are moderate-severe. Benzodiazepines are reserved for brief acute use only, as regular or as-needed use risks dependence and does not address the underlying disorder. Beta-blockers have no established role in panic disorder. Hospital admission is not indicated once cardiac causes are excluded.

• A. Admission is unnecessary once a cardiac cause has been excluded.
• B. Propranolol is not an evidence-based treatment for panic disorder.
• D. Keeping a benzodiazepine on hand encourages avoidance and reinforces reliance rather than treating the disorder.
• E. Daily benzodiazepine use for months risks tolerance and dependence and is not first-line.

Benzodiazepines enhance GABA-A receptor activity, producing rapid anxiolysis, but regular use beyond two to four weeks leads to pharmacodynamic tolerance and risk of physical dependence, with withdrawal symptoms including rebound anxiety, insomnia and seizures if stopped abruptly. They are therefore used short-term as a bridge while waiting for an antidepressant to take effect, then tapered rather than stopped suddenly. Long-term use is avoided given the risk of dependence without added efficacy over antidepressants for chronic anxiety.

• A. Benzodiazepines act on the GABA-A receptor, the same site modulated by alcohol, and share cross-tolerance and dependence potential.
• B. Indefinite combination use is not recommended because of dependence risk without added long-term benefit.
• C. Abrupt cessation after regular use risks withdrawal symptoms; a gradual taper is required.
• D. Benzodiazepines act rapidly within hours and are not dependent on months of continuous use for effect.

Social anxiety disorder is characterised by marked fear of specific social or performance situations in which the person may be scrutinised or judged, with preserved capacity for intimate relationships outside those triggers, as seen here. Avoidant personality disorder involves a pervasive, trait-level pattern of social inhibition, feelings of inadequacy and hypersensitivity to criticism across nearly all relationships and contexts, not limited to discrete performance situations. The distinction relies on the pervasiveness and onset pattern rather than the presence of social fear alone.

• A. Agoraphobia involves fear of situations where escape might be difficult, such as crowds or open spaces, not fear of social judgement specifically.
• B. Schizoid personality disorder features indifference to relationships and emotional detachment, not fear of judgement.
• C. Avoidant personality disorder requires pervasive social inhibition and inadequacy across most relationships, which this man does not show given his close friendships.
• D. Generalised anxiety disorder involves excessive worry across many areas of life, not fear restricted to social performance situations.

Acute stress disorder describes the characteristic cluster of intrusion, avoidance, negative mood, dissociative and arousal symptoms occurring within the first month after trauma exposure, as in this woman's presentation at eight days. A diagnosis of PTSD requires that symptoms persist for more than one month following the traumatic event; if her symptoms continue beyond four weeks, the diagnosis would then be reconsidered as PTSD. Adjustment disorder lacks the specific trauma-related intrusion and hyperarousal symptom clusters required for a trauma-specific diagnosis.

• A. There is no description of pervasive low mood or anhedonia meeting criteria for major depressive disorder.
• C. Adjustment disorder does not require a specific trauma-related symptom cluster and is a diagnosis of exclusion for less severe stressor reactions.
• D. There are no psychotic features such as delusions or hallucinations described.
• E. PTSD cannot be diagnosed until symptoms have persisted for more than one month after the traumatic event.

Trauma-focused psychological therapies, including trauma-focused CBT and eye movement desensitisation and reprocessing (EMDR), are first-line treatment for PTSD across major guidelines, with strong evidence for reducing intrusion, avoidance and hyperarousal symptoms by directly processing the traumatic memory. SSRIs such as sertraline are an option when trauma-focused therapy is unavailable, declined, or when response is inadequate, but are not preferred over psychological therapy as the initial approach. Engagement should be culturally appropriate, considering Aboriginal and Torres Strait Islander concepts of healing and connection to community where relevant.

• A. Generic supportive counselling without trauma processing is less effective than therapies specifically targeting the traumatic memory.
• B. Antipsychotics are not first-line and are reserved for specific refractory cases, not routine hyperarousal management.
• C. Benzodiazepines are not recommended in PTSD as they do not address core symptoms and carry dependence risk.
• D. Sertraline is an alternative or adjunct but trauma-focused psychological therapy is preferred as first-line treatment.

Obsessive-compulsive disorder is characterised by intrusive, unwanted thoughts (obsessions) recognised by the patient as excessive or irrational, which generate anxiety relieved temporarily by repetitive behaviours (compulsions), exactly as described. Insight that the thoughts and behaviours are excessive distinguishes OCD from psychotic disorders, where fixed false beliefs are held with full conviction and without recognition of their irrationality. Obsessive-compulsive personality disorder, in contrast, involves a pervasive trait pattern of perfectionism, rigidity and need for control, without the intrusive, anxiety-driven obsessions and compulsions seen here.

• A. Schizophrenia requires psychotic features such as delusions or hallucinations, and this man retains full insight that his thoughts are irrational.
• B. Delusional disorder involves fixed false beliefs held with conviction, unlike the recognised irrationality of this man's intrusive thoughts.
• C. Generalised anxiety disorder involves diffuse excessive worry about everyday events, not specific intrusive obsessions with ritualistic compulsions.
• D. Obsessive-compulsive personality disorder is a trait-based pattern of rigidity and perfectionism, not discrete intrusive obsessions with compulsive rituals.

A gradual onset of persecutory delusions and disorganised behaviour over several months, in a young adult with a negative urine drug screen, negative blood alcohol level and normal metabolic and thyroid investigations, is most consistent with a primary psychotic disorder such as schizophrenia. Substance-induced psychosis is excluded by the negative toxicology screen and typically presents with a more abrupt onset temporally related to intoxication or withdrawal. Delirium is excluded by the absence of acute fluctuating confusion or impaired consciousness, and normal thyroid function excludes an organic endocrine cause.

• A. Normal thyroid function tests exclude hyperthyroidism as the cause of his psychotic symptoms.
• B. Delirium presents with acute, fluctuating consciousness and attention disturbance, not a progressive four-month course with clear sensorium.
• C. A negative urine drug screen makes amphetamine-induced psychosis unlikely, and the gradual four-month course is atypical for stimulant-induced psychosis.
• D. A negative urine drug screen argues against cannabis-induced psychosis, which also typically resolves within days to weeks of abstinence.

In a young person presenting with first-episode psychosis, substance-induced psychosis, particularly from stimulants, cannabis or hallucinogens, is a common and readily identifiable organic cause that must be excluded early. A urine drug screen is inexpensive, rapid and directly actionable, and Therapeutic Guidelines recommend it as part of the initial work-up for new psychosis before considering more invasive or resource-intensive investigations. Neuroimaging and lumbar puncture are reserved for patients with atypical features such as fever, focal neurological signs, altered consciousness, or onset in middle age or older, none of which are present here. Addressing the most likely and easily tested cause first is consistent with a stepwise, evidence-based approach to new psychosis.

• A. MRI with contrast is a more invasive and costly test reserved for suspected structural, demyelinating or neoplastic causes, not a routine first-line test.
• C. CT brain is considered if there are focal neurological signs, head trauma, or atypical features, none of which this patient has.
• D. Lumbar puncture is indicated if encephalitis or other CNS infection is suspected, such as with fever, altered consciousness or meningism, which are absent here.
• E. EEG is used to evaluate suspected seizure-related or encephalopathic presentations, which are not suggested by this patient's history or examination.

Atypical antipsychotics are associated with weight gain, dyslipidaemia and insulin resistance, so Therapeutic Guidelines and RANZCP consensus recommend baseline measurement of weight, waist circumference, fasting glucose and lipid profile before starting therapy. These parameters should be reassessed at 3 months after initiation, when metabolic changes often become apparent, and then at least annually if stable. This structured monitoring allows early detection of antipsychotic-induced metabolic syndrome and timely intervention, such as switching agents or lifestyle modification. Mandatory full blood count monitoring applies specifically to clozapine because of agranulocytosis risk, not to risperidone.

• A. Monitoring only fasting glucose annually misses early weight gain and dyslipidaemia, which typically develop within the first few months.
• B. ECG monitoring alone is insufficient; metabolic parameters are the primary monitoring concern with atypical antipsychotics, although ECG may be considered for QT-prolonging agents.
• D. Routine monthly liver function tests are not a standard requirement for risperidone, unlike agents with known hepatotoxicity.
• E. Weekly full blood count monitoring is a clozapine-specific requirement due to agranulocytosis risk, not required for risperidone.

Clozapine is indicated for treatment-resistant schizophrenia, defined as inadequate response to at least two adequate trials of different antipsychotics. It carries a risk of life-threatening agranulocytosis, so a baseline full blood count with differential is mandatory before initiation, and regular monitoring (weekly for the first 18 weeks, then at least monthly thereafter under the Clozapine Patient Monitoring System) is a strict requirement for continued supply in Australia. This monitoring allows early detection of neutropenia so that clozapine can be withheld promptly to prevent progression to agranulocytosis. No other antipsychotic in Australia carries this mandatory haematological monitoring requirement.

• A. Lipid monitoring is important given clozapine's metabolic effects but is not the mandatory safety requirement that determines ongoing supply.
• B. Prolactin monitoring is more relevant to antipsychotics causing hyperprolactinaemia, such as risperidone, and clozapine typically causes minimal prolactin elevation.
• C. Renal function is not the specific mandatory monitoring parameter tied to clozapine's major safety risk.
• D. Thyroid function is not specifically mandated for clozapine initiation or monitoring, though it may be checked as part of general psychiatric work-up.

This patient has neuroleptic malignant syndrome, indicated by fever, generalised "lead-pipe" rigidity, autonomic instability and markedly elevated creatine kinase following a dose increase of a high-potency antipsychotic. The immediate priority is to stop the offending agent and provide intensive supportive care, including aggressive cooling, intravenous fluid resuscitation to prevent renal failure from rhabdomyolysis, and close monitoring in a high-dependency or intensive care setting. Dantrolene or bromocriptine may be used as adjunctive pharmacological therapy in severe or refractory cases, but they do not replace ceasing the causative drug and supportive management as the first step. Continuing or merely reducing the antipsychotic risks further deterioration and is inappropriate in this life-threatening emergency.

• A. Continuing the causative antipsychotic while adding dantrolene is inappropriate; the antipsychotic must be ceased as the first step, with dantrolene considered only as an adjunct in severe cases.
• B. Switching to another antipsychotic during an acute episode of neuroleptic malignant syndrome risks worsening the condition and is not appropriate until the episode has resolved.
• C. Benztropine treats acute dystonia and extrapyramidal symptoms, not the autonomic instability and rigidity of neuroleptic malignant syndrome.
• E. Dose reduction alone is inadequate; the causative antipsychotic must be stopped completely given the severity of this presentation.

Tardive dyskinesia is a delayed-onset movement disorder arising after months to years of antipsychotic exposure, classically producing involuntary choreoathetoid movements of the orofacial region, including lip-puckering, tongue protrusion and chewing movements. It is thought to result from dopamine receptor supersensitivity following prolonged dopamine blockade, particularly with long-term use of first-generation agents such as haloperidol. Unlike acute dystonia or parkinsonism, which occur early in treatment, tardive dyskinesia typically emerges after years of continuous therapy and can be irreversible even after stopping the causative drug. Management involves gradually reducing or switching the antipsychotic, with clozapine or valbenazine considered in refractory cases.

• A. Acute dystonic reactions occur within hours to days of starting or increasing an antipsychotic, not after years of stable treatment.
• B. Essential tremor presents as a postural or action tremor, typically of the hands, not orofacial dyskinetic movements.
• C. Akathisia presents as subjective inner restlessness with an inability to sit still, not involuntary orofacial movements.
• E. Parkinsonism from antipsychotics presents with bradykinesia, rigidity and tremor rather than orofacial choreoathetoid movements.

Delusional disorder is characterised by one or more non-bizarre delusions persisting for at least one month, in the absence of prominent hallucinations, thought disorder, or negative symptoms, with relatively preserved functioning outside the area affected by the delusion. This man's circumscribed, persistent belief with intact occupational and social functioning fits this picture. Schizophrenia requires broader deterioration in functioning and typically additional features such as hallucinations, disorganised speech, or negative symptoms. The distinction matters because delusional disorder carries a better prognosis and different management emphasis, often requiring less intensive psychosocial support.

• A. Schizophreniform disorder requires schizophrenia-like symptoms lasting 1–6 months with broader psychotic features, not an isolated circumscribed delusion of over a year.
• B. Paranoid schizophrenia requires additional psychotic features and marked functional decline, which are absent here.
• C. Schizoaffective disorder requires a concurrent major mood episode alongside psychotic symptoms, which is not described.
• E. Brief psychotic disorder lasts less than one month, inconsistent with this 14-month history.

Symptom-triggered benzodiazepine dosing using a validated withdrawal scale such as the AWS is the standard approach to alcohol withdrawal management per Therapeutic Guidelines, as it titrates medication to symptom severity and reduces total benzodiazepine exposure compared with fixed dosing. Diazepam is preferred due to its long half-life, which provides a smoother withdrawal course with self-tapering effect. Regular monitoring and reassessment every 1–2 hours initially allows timely escalation if withdrawal progresses to delirium tremens or seizures. This patient's moderate symptoms without complications do not yet warrant ICU-level care.

• A. Haloperidol does not address the GABA-glutamate dysregulation underlying withdrawal and does not prevent seizures or delirium tremens; it has a role only as an adjunct for severe agitation or hallucinosis refractory to benzodiazepines.
• C. Propranolol may mask autonomic signs of worsening withdrawal and does not prevent seizures or delirium tremens, so it is not used as monotherapy.
• D. Baclofen is not first-line for acute alcohol withdrawal under Australian guidelines.
• E. This patient's withdrawal is moderate and oral therapy is appropriate; IV infusion and ICU admission are reserved for severe or complicated withdrawal.

In a patient with suspected thiamine deficiency presenting with hypoglycaemia, intravenous thiamine should be given before or at the same time as glucose, because administering glucose alone can precipitate or worsen Wernicke encephalopathy by consuming remaining thiamine stores in carbohydrate metabolism. This patient already shows classic signs of Wernicke encephalopathy (confusion, nystagmus, ataxia), making urgent thiamine replacement critical regardless of glucose correction. Therapeutic Guidelines recommend thiamine be given promptly, ideally preceding dextrose when feasible, in any at-risk patient requiring glucose. Delaying thiamine risks irreversible neurological damage, including Korsakoff syndrome.

• A. Giving dextrose first and delaying thiamine until the next day risks precipitating or worsening Wernicke encephalopathy.
• B. Wernicke encephalopathy is a clinical diagnosis; waiting for imaging would dangerously delay treatment of both hypoglycaemia and thiamine deficiency.
• D. Giving them simultaneously is acceptable practice but the correct principle in a patient with evident Wernicke signs and significant hypoglycaemia is to prioritise thiamine first given the urgency of neurological risk.
• E. Glucagon is not appropriate here since IV access is already available, and oral thiamine is inadequately absorbed in malnourished alcohol-dependent patients.

This patient has delirium tremens, a medical emergency characterised by autonomic hyperactivity (tachycardia, hypertension, fever, diaphoresis), disorientation, and hallucinations, typically occurring 48–96 hours after the last drink. Delirium tremens carries significant mortality if untreated and requires escalation to a high-dependency or intensive care setting with intravenous benzodiazepine administration, often at high doses, under close monitoring for airway protection and cardiovascular stability. Oral protocols used for uncomplicated withdrawal are insufficient once delirium tremens has developed. Early recognition and urgent escalation are critical to reducing morbidity and mortality.

• A. Standard oral symptom-triggered protocols are inadequate once frank delirium tremens with autonomic instability has developed; parenteral therapy in a monitored setting is required.
• B. While culturally appropriate support is important to arrange, it does not substitute for immediate medical treatment of a life-threatening emergency.
• C. Delirium tremens is a medical emergency and reassurance with delayed reassessment risks deterioration and death.
• D. Antipsychotic monotherapy does not address the underlying withdrawal pathophysiology or prevent seizures, and discharge planning is inappropriate during an acute emergency.

The AUDIT-C is a brief three-item screening tool derived from the full AUDIT questionnaire, recommended by the RACGP Red Book for routine opportunistic screening of at-risk alcohol consumption in general practice due to its brevity, ease of use, and strong validated sensitivity for detecting hazardous and harmful drinking. It asks about frequency, typical quantity, and frequency of heavy episodic drinking. The CAGE questionnaire is more oriented toward detecting dependence rather than at-risk drinking patterns and is less sensitive in general population screening. SADQ and CIWA-Ar are used to assess dependence severity and withdrawal symptoms respectively, not for initial screening.

• A. CAGE is better suited to detecting alcohol dependence rather than identifying at-risk drinking in a low-prevalence general practice population.
• B. SADQ assesses severity of established dependence, not screening for at-risk drinking.
• D. MAST is a longer instrument less practical for routine opportunistic screening in general practice.
• E. CIWA-Ar is used to assess the severity of withdrawal symptoms in patients already undergoing detoxification, not for screening.

Opioid substitution therapy (OST) with buprenorphine or methadone is first-line management for opioid dependence according to Australian guidelines, substantially reducing mortality, injecting-related harm, and criminal activity compared with abstinence-based approaches alone. Induction should occur under medical supervision, particularly with buprenorphine given its partial agonist properties and precipitated withdrawal risk if commenced too soon after last opioid use. This patient's chronic dependence, repeated failed abstinence attempts, and ongoing injecting make him an appropriate candidate for OST, which should be initiated promptly rather than delayed. Psychosocial counselling is a valuable adjunct but is not sufficient alone for established opioid dependence.

• A. Naltrexone requires a period of opioid abstinence first and carries risk of precipitated withdrawal if given to an opioid-dependent patient still using heroin.
• B. Abrupt withdrawal has high relapse rates and does not address long-term harm reduction as effectively as substitution therapy.
• C. Oxycodone is not an approved opioid substitution medication and carries its own misuse and diversion risks.
• E. Delaying medication for three months of counselling alone fails to address ongoing injecting-related harm and overdose risk in an opioid-dependent patient.

Provision of take-home naloxone with education for the patient and people likely to witness a future overdose is recommended practice following an opioid overdose, as it directly reduces mortality from subsequent overdose events, particularly in patients living alone with ongoing opioid use. Take-home naloxone programs are supported by Australian harm-reduction policy and should be offered opportunistically at every overdose presentation, alongside referral to drug and alcohol services and discussion of opioid substitution therapy. Overdose survivors are at high risk of recurrent overdose, especially in the following weeks, making this intervention time-critical rather than something to defer to routine follow-up.

• B. Overdose survivors remain at high risk of recurrence; failing to intervene misses a critical harm-reduction opportunity.
• C. Diazepam is not indicated for opioid withdrawal management and carries its own risks of misuse and respiratory depression when combined with opioids.
• D. Compulsory detoxification is not supported by mental health legislation for substance use alone and is not standard practice.
• E. Routine follow-up in a month does not address the immediate ongoing risk of fatal overdose recurrence.

Delirium is defined by acute onset (hours to days), a fluctuating course, and impaired attention and arousal, distinguishing it from dementia, which develops insidiously over months to years with relatively stable attention until late stages. This patient's 2-day change with fluctuating alertness, inattention and fever suggests an acute precipitant such as infection causing delirium superimposed on her underlying mild cognitive impairment. Her long-standing gradual memory decline is consistent with an underlying dementia process but does not explain the acute change. Identifying delirium is critical because it signals an underlying medical cause requiring urgent assessment and treatment.

• A. Chronic word-finding difficulty is consistent with longstanding dementia, not an acute confusional state.
• B. Family history relates to dementia risk and does not help distinguish an acute delirious episode from chronic cognitive decline.
• C. Difficulty with activities of daily living is a feature of dementia severity and does not help distinguish an acute delirium from chronic decline.
• D. Gradual decline over years reflects her underlying baseline dementia, not the acute change that defines delirium.

This patient has delirium, most likely precipitated by a postoperative complication such as a catheter-associated urinary tract infection, hypoxia, or another acute medical cause, given his fever, tachycardia and reduced oxygen saturation. The most appropriate next step is a focused assessment to identify and treat the underlying precipitant, which is the cornerstone of delirium management, rather than simply sedating or restraining the patient. Addressing reversible causes such as infection, hypoxia, pain, constipation or medication effects often resolves delirium without needing pharmacological agents. Non-pharmacological strategies (reorientation, normalising sleep-wake cycle, involving family) support recovery but do not replace treating the cause.

• A. Physical restraint increases agitation and risk of injury and is not an appropriate substitute for identifying and treating the cause.
• B. This presentation is not an expected, benign postoperative state; it reflects delirium requiring urgent evaluation for a treatable cause.
• D. Delirium is a medical emergency requiring assessment for an organic precipitant; transfer to psychiatry delays appropriate medical treatment.
• E. Antipsychotics may be considered for severe agitation causing risk of harm but do not address the underlying medical cause and are not first-line management.

The Kimberley Indigenous Cognitive Assessment (KICA) was specifically developed and validated for use in older Aboriginal and Torres Strait Islander people, particularly in remote communities, accounting for differences in education, language and cultural context that limit the validity of mainstream tools. The MMSE and MoCA were developed and normed on predominantly Western, English-speaking, highly educated populations and have reduced validity and specificity in patients with limited formal education or English as a second language, often leading to false-positive impairment. The ACE-III has similar limitations to the MMSE and MoCA in this population. A clock drawing test alone lacks sufficient sensitivity and specificity to be used as a standalone screening tool.

• A. The MoCA, like the MMSE, is normed on educated English-speaking populations and tends to overestimate impairment in this context.
• B. The MMSE is heavily influenced by education level and English language proficiency, reducing its validity in this patient.
• C. Clock drawing alone is not a validated standalone screening tool and lacks adequate sensitivity and specificity.
• D. The ACE-III shares the same language and education-based limitations as the MMSE and MoCA for this population.

Dementia with Lewy bodies is characterised by the core features of fluctuating cognition, recurrent visual hallucinations, REM sleep behaviour disorder (acting out dreams) and spontaneous parkinsonism, often with relatively preserved early memory but prominent visuospatial impairment, matching this patient's presentation. Alzheimer disease typically presents with early, progressive episodic memory loss without early hallucinations or parkinsonism. Vascular dementia presents with a stepwise decline associated with cerebrovascular risk factors and focal neurological signs rather than hallucinations and REM sleep behaviour disorder. Frontotemporal dementia usually presents with behavioural or language changes rather than hallucinations and parkinsonism. The distinction from Parkinson disease dementia is based on timing: in Lewy body dementia, cognitive symptoms precede or arise within a year of parkinsonism, whereas Parkinson disease dementia follows established motor disease of more than a year's duration.

• A. Vascular dementia typically shows a stepwise decline linked to vascular risk factors and focal deficits, not fluctuating cognition with hallucinations and REM sleep behaviour disorder.
• B. Frontotemporal dementia usually presents with early behavioural disinhibition or language impairment rather than hallucinations and parkinsonism.
• C. Alzheimer disease classically presents with prominent early episodic memory loss, not early visual hallucinations, fluctuating cognition and parkinsonism.
• E. Parkinson disease dementia requires cognitive decline developing after an established diagnosis of Parkinson disease of more than one year, whereas here cognitive and motor features appear close together.

Patients with dementia with Lewy bodies (and Parkinson disease dementia) have a well-documented neuroleptic sensitivity, particularly to typical antipsychotics, which can precipitate severe worsening of parkinsonism, marked sedation, autonomic dysfunction and even acute deterioration or death. This is thought to relate to pre-existing dopaminergic deficits and nigrostriatal pathology. Therapeutic Guidelines recommend avoiding antipsychotics where possible in DLB and, if essential for severe psychotic symptoms, using the lowest possible dose of a better-tolerated agent such as quetiapine with close monitoring. Non-pharmacological strategies and treating reversible precipitants should be tried first.

• B. Neuroleptic malignant syndrome is a rare idiosyncratic reaction that evolves over days, not minutes, and is not specific to DLB.
• C. QT prolongation is a recognised antipsychotic risk but is not the specific, defining sensitivity reaction seen in Lewy body dementia.
• D. Tardive dyskinesia develops with chronic exposure, not after a single dose, and is not the specific concern highlighted in DLB.
• E. Acute dystonia can occur with antipsychotics generally but is not the characteristic severe sensitivity reaction of DLB.

Behavioural and psychological symptoms of dementia (BPSD), such as this pattern suggestive of 'sundowning', should first be managed with non-pharmacological strategies once reversible medical causes (infection, pain, constipation, medication effects) have been excluded, as in this case. Strategies include maintaining consistent routines, optimising the environment, ensuring adequate daytime activity and light exposure, and staff training in person-centred care. Antipsychotics and benzodiazepines carry significant risks in older people with dementia, including falls, sedation, stroke and increased mortality, and should be reserved for severe symptoms causing risk of harm that do not respond to non-pharmacological measures. Hospital transfer is not indicated when there is no acute medical concern.

• A. Antipsychotics are associated with increased stroke and mortality risk in dementia and should only be used after non-pharmacological measures fail and symptoms are severe.
• B. There is no acute medical indication for hospital transfer given normal vital signs and a clear reversible cause has been excluded.
• C. Cholinesterase inhibitors are used for cognitive symptoms of dementia, not as a first-line treatment for acute behavioural disturbance.
• E. Benzodiazepines increase falls and confusion risk in older people and are not first-line for BPSD.

A diagnosis of ADHD requires symptoms of inattention and/or hyperactivity-impulsivity to be present before age 12, persist for at least six months, and cause functional impairment in two or more settings (for example, home and school), as per DSM-5 criteria used in Australian practice. Information should be gathered from multiple informants, such as parents and teachers, rather than relying on a single source. Diagnosis is clinical; neuroimaging, EEG and IQ testing are not required unless there is a specific indication such as suspected comorbid learning disability or neurological disease. Response to stimulant medication is not diagnostic, as it can occur in children without ADHD.

• A. EEG is not part of routine ADHD diagnostic workup unless seizures are suspected clinically.
• C. Response to stimulants is non-specific and does not confirm the diagnosis, as many children without ADHD also show improved attention with stimulants.
• D. IQ testing is not required to diagnose ADHD unless a comorbid intellectual or specific learning disability is suspected.
• E. Diagnosis requires corroboration from more than one setting and informant, not a single source, and symptoms must be present for at least six months, not one month.

Before starting stimulant medication for ADHD, a careful personal and family cardiac history and examination should be performed to screen for risk factors such as syncope, palpitations, exertional symptoms, or a family history of sudden cardiac death, long QT syndrome or cardiomyopathy. In the absence of such red flags, baseline heart rate, blood pressure and weight should be recorded and routine investigations such as ECG or echocardiogram are not required. If any red flags are identified, cardiology referral and further investigation such as ECG are warranted before initiating treatment. Stimulants are then monitored with regular review of growth, blood pressure and heart rate.

• A. Holter monitoring is reserved for patients with symptoms suggestive of arrhythmia, not routine pre-treatment screening.
• B. Echocardiogram is not routinely required in the absence of cardiac symptoms or relevant family history.
• C. Cardiology review is only needed if red flags are present on history or examination, which are absent here.
• D. Routine ECG is not required for all children before starting stimulants; it is reserved for those with cardiac red flags.

This child shows features in both core domains required for a diagnosis of autism spectrum disorder: persistent deficits in social communication and interaction (lack of eye contact, not responding to name, absence of joint attention through pointing) and restricted, repetitive patterns of behaviour (distress with routine change, repetitive lining up of toys, lack of pretend play). These features are present across multiple contexts and are beyond what is expected for normal developmental variation at this age. Early recognition is important, as it is associated with better outcomes following early intervention, and in Australia confirmed diagnosis is typically made by a paediatrician or psychiatrist using a multidisciplinary assessment.

• A. Selective mutism involves failure to speak in specific social situations despite speaking normally elsewhere, not a global lack of pointing, eye contact and pretend play.
• B. Global developmental delay involves delay across all domains including motor and cognitive skills, which is not specifically described here; the pattern described is characteristic of autism.
• C. Expressive language disorder affects language production alone and does not explain the lack of eye contact, joint attention or repetitive behaviours seen here.
• D. The combination of absent joint attention, lack of response to name, restricted interests and repetitive behaviour is beyond normal variation in temperament.

Conduct disorder is characterised by a repetitive and persistent pattern of behaviour violating the basic rights of others or major age-appropriate societal norms, including aggression towards people or animals, destruction of property (such as fire-setting), deceitfulness or theft, and serious rule violations such as truancy, over at least 12 months. This boy's shoplifting, fire-setting, truancy and physical aggression causing injury meet these criteria. Oppositional defiant disorder involves a pattern of angry, defiant and vindictive behaviour towards authority figures without the serious violations of others' rights or property seen in conduct disorder. Antisocial personality disorder cannot be diagnosed before age 18.

• A. Intermittent explosive disorder involves isolated impulsive aggressive outbursts, not a broader pattern including theft, truancy and property destruction.
• B. Oppositional defiant disorder lacks the serious violations of others' rights or property, such as theft, fire-setting and aggression causing injury, seen here.
• D. Adjustment disorder requires an identifiable psychosocial stressor with onset within three months, which is not described in this persistent 12-month pattern.
• E. Antisocial personality disorder requires the person to be at least 18 years old and is not diagnosed in a 13-year-old.

This patient has anorexia nervosa with severe medical instability, indicated by marked bradycardia (heart rate 38 beats per minute), hypotension and hypothermia, all of which are recognised indications for urgent hospital admission according to Therapeutic Guidelines and RACGP recommendations. Outpatient management, day programs or medication are inappropriate when there are signs of cardiovascular compromise, as these patients are at risk of arrhythmia and sudden cardiac death. Admission allows close cardiac monitoring, careful medical stabilisation and a supervised, cautious approach to refeeding to reduce the risk of refeeding syndrome.

• A. Medication is not the priority; this patient requires urgent medical stabilisation for cardiovascular compromise, not pharmacotherapy.
• B. A day program is inappropriate given signs of significant medical instability requiring inpatient monitoring.
• D. Outpatient management is unsafe given the severe bradycardia, hypotension and hypothermia indicating medical instability.
• E. Discharge home is unsafe in the setting of severe bradycardia, hypotension and hypothermia, which carry a risk of cardiac arrhythmia.

Refeeding syndrome results from a sudden shift from catabolic to anabolic metabolism when carbohydrate intake is reintroduced after a period of starvation, causing an insulin surge that drives phosphate, potassium and magnesium intracellularly, leading to hypophosphataemia, hypokalaemia and hypomagnesaemia. Hypophosphataemia is the hallmark biochemical finding and can cause muscle weakness, rhabdomyolysis, cardiac arrhythmia, respiratory failure and fluid retention including peripheral oedema and cardiac failure. Therapeutic Guidelines recommend starting refeeding cautiously, with daily monitoring of electrolytes including phosphate, potassium and magnesium, and phosphate supplementation, particularly in the first week of refeeding in high-risk patients.

• B. Refeeding syndrome is associated with low, not high, calcium due to electrolyte shifts and reduced intake during starvation.
• C. Sodium disturbance is not the characteristic biochemical feature of refeeding syndrome; fluid retention can occur but hypernatraemia is not typical.
• D. Refeeding causes potassium to shift intracellularly, leading to hypokalaemia, not hyperkalaemia.
• E. Refeeding causes phosphate to shift intracellularly, causing hypophosphataemia, not hyperphosphataemia.

Bulimia nervosa is characterised by recurrent binge eating with a sense of loss of control, followed by compensatory behaviours such as self-induced vomiting, occurring at least once weekly for three months, in a patient who is not significantly underweight. The parotid swelling (sialadenosis), dental erosion from gastric acid, and Russell's sign (calluses on the knuckles from inducing vomiting) are classic examination findings. Hypokalaemia results from repeated vomiting and is an important medical complication to screen for. Her normal BMI distinguishes this from anorexia nervosa, where significant low weight is required.

• A. This disorder involves avoidance of food based on sensory characteristics or fear of consequences, not binge-purge cycles.
• B. Binge eating disorder lacks the compensatory behaviours (vomiting, Russell's sign, dental erosion) seen here.
• D. Rumination disorder involves effortless regurgitation of recently swallowed food, not binge eating with purging.
• E. This diagnosis requires a BMI below 18.5 kg/m² or significant low weight, which this patient does not have.

This presentation, with a pervasive pattern of unstable relationships, identity disturbance, fear of abandonment and recurrent self-harm beginning in early adulthood, is characteristic of borderline personality disorder. Dialectical behaviour therapy (DBT) is the first-line, evidence-based psychological treatment, combining individual therapy and skills training in mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness. Therapeutic Guidelines recommend structured psychological therapy as the mainstay of treatment, with medication reserved for short-term management of specific crisis symptoms or comorbidities rather than as a primary treatment. No pharmacotherapy has demonstrated sustained efficacy for the core features of borderline personality disorder.

• B. This is an older, less evidence-based and more resource-intensive approach than DBT, which is the current guideline-recommended first-line therapy.
• C. Mood stabilisers are not first-line and lack robust evidence for borderline personality disorder without a comorbid mood disorder.
• D. Antidepressants have not shown consistent efficacy for the core features of borderline personality disorder and are not first-line.
• E. Antipsychotics may be used short-term for crisis-related symptoms but are not first-line treatment for the disorder itself.

This patient demonstrates Hoover's sign, a positive clinical finding where involuntary hip extension of the 'weak' leg occurs during contralateral hip flexion against resistance, indicating normal corticospinal pathways despite apparent paralysis. Functional neurological disorder is diagnosed on the basis of such positive physical signs demonstrating internal inconsistency, rather than by exclusion alone, in a patient with genuine distress and no evidence of conscious symptom production. Normal reflexes, tone and imaging further support a functional rather than structural cause. The temporal link to psychological stress is supportive but not required for diagnosis.

• B. This involves conscious fabrication or induction of symptoms to assume the sick role, not an unconscious functional process.
• C. This condition typically presents with ascending symmetrical weakness and areflexia following a preceding infection, not a positive Hoover's sign.
• D. This typically shows signs of central nervous system demyelination on MRI and a relapsing-remitting or progressive course, not a positive Hoover's sign with normal imaging.
• E. Malingering involves conscious, deliberate symptom production for external gain, which is not indicated here.

Postpartum psychosis is a psychiatric emergency that typically presents within the first two weeks postpartum with rapid onset of mood lability, disorganisation, delusions, hallucinations and insomnia, as seen here. It carries a significant risk of harm to both the mother and the infant, including infanticide and suicide, and requires urgent psychiatric admission, ideally to a specialised mother-baby unit to allow ongoing bonding and breastfeeding under close supervision. Antipsychotic medication, often combined with a mood stabiliser, is usually required, and risk assessment regarding the infant's safety is essential. This differs markedly from the self-limiting, milder baby blues.

• A. This delay is dangerous given the acuity of psychotic symptoms and the risk of harm to mother and infant.
• B. Antidepressant monotherapy in the community is inadequate and unsafe for an acute psychotic episode with risk to the infant.
• C. Psychotic symptoms with disorganisation and delusional beliefs are not a normal adjustment reaction and require urgent intervention.
• D. This level of care is insufficient for an acute psychiatric emergency with psychotic features.

Baby blues is the most common and mildest presentation, affecting up to 80% of new mothers, with transient tearfulness and mood lability peaking days three to five postpartum and resolving spontaneously within two weeks, requiring only reassurance and support. Postnatal depression typically has a more gradual onset, persisting beyond two weeks and often diagnosed within the first six weeks to twelve months postpartum, requiring active screening (for example with the Edinburgh Postnatal Depression Scale) and treatment. Postpartum psychosis has the most abrupt onset, usually within the first two to four weeks, and is a psychiatric emergency due to the presence of psychotic features and risk to mother and infant. Correctly distinguishing these timelines guides appropriate urgency of response.

• B. This incorrectly sequences postnatal depression before postpartum psychosis and blues last.
• C. This reverses the order of baby blues and postnatal depression, which have distinct onset and resolution patterns.
• D. This reverses the entire sequence from most severe/acute to mildest/most common.
• E. This places postpartum psychosis before postnatal depression, inconsistent with the described gradual versus abrupt onset patterns.

Decision-making capacity is decision-specific and time-specific, and must never be assumed to be absent simply because a person has a psychiatric diagnosis or because their decision seems unwise. The correct approach is a formal capacity assessment evaluating whether the patient can understand relevant information about the treatment, retain it, weigh it in the balance to arrive at a decision, and communicate that decision. This patient shows no current evidence of psychotic symptoms affecting his reasoning, so capacity should not be presumed absent. If he is found to have capacity, his refusal of treatment, even if clinically unwise, must be respected under Australian guardianship and consent law.

• A. A capacitous adult's own decision takes precedence over substitute decision-makers; next of kin consent is not sought unless the patient lacks capacity.
• C. Covert administration without consent breaches patient autonomy and is unlawful if the patient has intact decision-making capacity.
• D. Mental Health Act orders require that the refusal arises from mental illness-related impairment and other criteria such as risk of serious harm; this has not yet been established and a capacity assessment must come first.
• E. A psychiatric diagnosis alone does not equate to incapacity; capacity is decision-specific and must be formally assessed.

The Mental Health Act pathway applies specifically to involuntary treatment of a mental illness where the person's decision-making is impaired by that illness and criteria such as risk of serious harm to self or others and lack of less restrictive alternatives are met, as in this woman's acute mania. Guardianship and substitute decision-making legislation (such as enduring guardianship or tribunal-appointed decision-makers) applies when a person lacks capacity for a specific treatment decision due to a cognitive or other impairment, but is not detained or treated for an acute mental illness crisis, as with this man's dementia and hip fracture. These are distinct legal frameworks with different thresholds, safeguards and purposes, and mixing them inappropriately risks using the wrong level of restriction and oversight for each clinical situation. Mental Health Acts across Australian jurisdictions are reserved for mental illness, not all causes of incapacity.

• A. Capacity-impaired refusal and mental illness-impaired refusal meeting statutory criteria can both permit treatment without consent, via guardianship and Mental Health Act pathways respectively.
• B. The woman's acute mania with risk of harm meets Mental Health Act criteria, not guardianship pathways, which are for incapacity without an acute mental illness emergency.
• C. Dementia-related incapacity without an acute treatable mental illness crisis is not an appropriate basis for Mental Health Act detention.
• D. Dementia is a cognitive impairment managed under guardianship frameworks, not grounds for Mental Health Act detention, which requires a treatable mental illness crisis with risk criteria.